Improved influenza vaccines: full value vaccine assessment
World Health Organization
Jan 2026 · World Health Organization
Ebook
78
Pages
family_home
Eligible
info
About this ebook
Seasonal influenza remains a major global public health challenge, causing substantial morbidity and mortality each year. The World Health Organization (WHO) conducted the Full Value of Improved Influenza Vaccine Assessment (FVIVA) to evaluate the health, economic, and policy impacts of next-generation influenza vaccines and identify barriers to their uptake.
The FVIVA examines the vaccine development pipeline, quantifies projected health and economic benefits, assesses financial viability for manufacturers, and identifies country preferences and implementation challenges. It provides a basis to guide investment, policy decisions, and introduction strategies—supporting stronger seasonal programs and enhanced pandemic preparedness.
Using a mixed-methods approach—including literature review, stakeholder engagement, and quantitative modeling—the FVIVA estimates that broad use of improved vaccines could prevent 6.6–18 billion additional influenza cases, 2.3–6.2 million deaths, and 21–57 million disability-adjusted life years (DALYs) globally between 2025 and 2050. Economic modeling suggests cost-effectiveness of such vaccines in 9–48% of countries at the lowest assumed price point. The FVVA furthermore describes the proposed financial value to develop and commercialize improved influenza vaccines, in both established and emerging markets.
The FVIVA emphasizes that collaboration among developers, manufacturers, donors, multilateral organizations, and policymakers is essential to maximize public health impact and strengthen global pandemic preparedness.
The FVIVA examines the vaccine development pipeline, quantifies projected health and economic benefits, assesses financial viability for manufacturers, and identifies country preferences and implementation challenges. It provides a basis to guide investment, policy decisions, and introduction strategies—supporting stronger seasonal programs and enhanced pandemic preparedness.
Using a mixed-methods approach—including literature review, stakeholder engagement, and quantitative modeling—the FVIVA estimates that broad use of improved vaccines could prevent 6.6–18 billion additional influenza cases, 2.3–6.2 million deaths, and 21–57 million disability-adjusted life years (DALYs) globally between 2025 and 2050. Economic modeling suggests cost-effectiveness of such vaccines in 9–48% of countries at the lowest assumed price point. The FVVA furthermore describes the proposed financial value to develop and commercialize improved influenza vaccines, in both established and emerging markets.
The FVIVA emphasizes that collaboration among developers, manufacturers, donors, multilateral organizations, and policymakers is essential to maximize public health impact and strengthen global pandemic preparedness.
Seasonal influenza remains a major global public health challenge, causing substantial morbidity and mortality each year. The World Health Organization (WHO) conducted the Full Value of Improved Influenza Vaccine Assessment (FVIVA) to evaluate the health, economic, and policy impacts of next-gene...
Rate this ebook
Tell us what you think.
Reading information
Smartphones and tablets
Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.
Laptops and computers
You can listen to audiobooks purchased on Google Play using your computer's web browser.
eReaders and other devices
To read on e-ink devices like Kobo eReaders, you'll need to download a file and transfer it to your device. Follow the detailed Help Center instructions to transfer the files to supported eReaders.
